Birelentinib
Preclinical
Birelentinib is one of 21 therapeutic programs targeting Diffuse Large B-cell Lymphoma(DLBCL). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
21 competitors in Diffuse Large B-Cell Lymphoma(dlbcl)
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Polivy
RochePhase 2
COLUMVI
RochePhase 2
Gazyva
RochePhase 2
Gemzar
Johnson & JohnsonPhase 2
Eloxatin
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Birelentinib. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- DDizal Pharmaceuticals